8-硝基-1,3,4,5-四氢-2H-1-苯并吖庚因-2-酮 | 22246-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 8-硝基-1,3,4,5-四氢-2H-1-苯并吖庚因-2-酮
• 中文别名: 8-硝基-1,3,4,5-四氢-2H-1-苯并氮杂卓-2-酮
• 英文名称: 8-nitro-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one
• 英文别名: 8-nitro-1,3,4,5-tetrahydro-benzo[b]azepin-2-one；8-nitro-2,3,4,5-tetrahydro-1H-1-benzazepin；8-nitro-1,3,4,5-tetrahydro-benzo[b]azepin-2-one；8-nitro-1,3,4,5-tetrahydro-benz[b]azepin-2-one；8-Nitro-1,3,4,5-tetrahydro-benz[b]azepin-2-on；2,3,4,5-tetrahydro-8-nitro-2-oxo-1H-1-benzazepine；8-nitro-1,3,4,5-tetrahydro-1-benzazepin-2-one
• CAS: 22246-79-3
• 化学式: C₁₀H₁₀N₂O₃
• 分子量: 206.201
• InChiKey: SSTQWTAKTYMLTB-UHFFFAOYSA-N

物化性质

• 熔点：
  224-226 °C(Solv: ethanol (64-17-5))
• 沸点：
  408.8±45.0 °C(Predicted)
• 密度：
  1.301±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  8-硝基-1,3,4,5-四氢-2H-1-苯并吖庚因-2-酮 在 10% palladium on activated carbon 、 一水合肼 作用下， 以 乙醇 为溶剂， 生成 8-氨基-1,3,4,5-四氢-苯并[b]氮杂革-2-酮
  参考文献：
  名称：

  Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors

  摘要：

  The HGF-c-Met signaling axis is an important paracrine mediator of epithelial-mesenchymal cell interactions involving the regulation of multiple cellular activities including cell motility, mitogenesis, morphogenesis, and angiogenesis. Dysregulation of c-Met signaling (e. g., overexpression or increased activation) is associated with the development of a wide range of tumor types; thus, inhibiting the HGF-c-Met pathway is predicted to lead to anti-tumor effects in many cancers. Elaboration of a 2-arylaminopyrimidine scaffold led to a series of potent c-Met inhibitors bearing a C4-2-amino-N-methylbenzamide group. Specifically, a series of C2-benzazepinone analogs demonstrated potent inhibition of c-Met in enzymatic and cellular assays. Kinase selectivity could be tuned by varying the nature of the alkyl group on the benzazepinone nitrogen. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.045
• 作为产物：
  描述：

  7-硝基-3,4-二氢-2H-1-萘酮 在 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 反应 17.0h， 生成 8-硝基-1,3,4,5-四氢-2H-1-苯并吖庚因-2-酮
  参考文献：
  名称：

  [EN] NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF
  [FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  本发明涉及式(I)化合物的制备过程及其治疗用途：其中R6是-CONH2或一个-C(Rα)(Rβ)(OH)基团；R是一个取代的苯基或杂芳基团；R7是一个可选地取代的芳基或杂芳基团。

  公开号：

  WO2013150036A1

文献信息

• [EN] NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013150036A1

  公开（公告）日：2013-10-10

  The present invention relates to compounds of formula (I): wherein R6 is -CONH2 or a -C(Rα)(Rβ)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.

  本发明涉及式(I)化合物的制备过程及其治疗用途：其中R6是-CONH2或一个-C(Rα)(Rβ)(OH)基团；R是一个取代的苯基或杂芳基团；R7是一个可选地取代的芳基或杂芳基团。
• Carboxamides and anilides
  申请人：Hoffmann-La Roche Inc.

  公开号：US05216148A1

  公开（公告）日：1993-06-01

  Described herein are compounds of the formula ##STR1## wherein R.sup.1 signifies hydrogen, lower-alkyl or a cation; R.sup.2 signifies hydrogen, lower-alkyl, lower-alkoxy or halogen; M signifies --CONH-- or --NHCO--; X and Y are each independently selected from the group consisting of >CR.sup.3 R.sup.4 and --CONR.sup.5 --; Z signifies >CR.sup.6 R.sup.7 ; R.sup.3, R.sup.4, R.sup.6 and R.sup.7 are each independently selected from the group consisting of hydrogen and lower-alkyl; R.sup.5 signifies alkyl; and n signifies 0, 1 or 2; provided that at least one of X or Y is --CONR.sup.5 -- which is bonded to the phenyl ring via the N atom. These compounds are useful in the treatment and prophylaxis of neoplasms, dermatoses and aging of the skin.

  本文描述了以下公式的化合物##STR1##其中R.sup.1表示氢、较低的烷基或阳离子；R.sup.2表示氢、较低的烷基、较低的烷氧基或卤素；M表示--CONH--或--NHCO--；X和Y分别独立地选自>CR.sup.3 R.sup.4和--CONR.sup.5--的组成；Z表示>CR.sup.6 R.sup.7；R.sup.3、R.sup.4、R.sup.6和R.sup.7分别独立地选自氢和较低的烷基；R.sup.5表示烷基；n表示0、1或2；前提是X或Y中至少有一个是通过N原子与苯环结合的--CONR.sup.5--。这些化合物在治疗和预防肿瘤、皮肤病和皮肤老化方面具有用途。
• Substituted 1-benzazepines and derivatives thereof
  申请人：Tomazic Alenka

  公开号：US20050234041A1

  公开（公告）日：2005-10-20

  This invention relates to substituted 1-benzazepines and derivatives thereof useful as anti-infective agents, to compositions, including pharmaceutical compositions, comprising such compounds, to processes for making these compounds and to methods of using these compounds for killing bacteria and other microorganisms or inhibiting bacterial and other microorganism growth.

  本发明涉及取代的1-苯并氮杂环和其衍生物，其作为抗感染剂有用，包括制备这些化合物的组合物，包括药物组合物，制备这些化合物的过程以及使用这些化合物杀死细菌和其他微生物或抑制细菌和其他微生物生长的方法。
• Enzyme modulators and treatments
  申请人：Flynn L. Daniel

  公开号：US20070078121A1

  公开（公告）日：2007-04-05

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, immunological disorders, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of kinases, including p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein, comprises the step of contacting said kinase protein with the novel compounds.

  提供了新型化合物及其使用方法，用于治疗炎症性疾病、免疫性疾病、过度增生性疾病、癌症以及以高血管化为特征的疾病。在一种优选实施方式中，调节激酶的激活状态，包括p38激酶蛋白、abl激酶蛋白、bcr-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白，包括将该激酶蛋白与新型化合物接触的步骤。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。